Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study

Hiroshi Kurahara,Hiroyuki Shinchi,Takao Ohtsuka,Yoshihiro Miyasaka,Taketo Matsunaga,Hirokazu Noshiro,Tomohiko Adachi,Susumu Eguchi,Naoya Imamura,Atsushi Nanashima,Kazuhiko Sakamoto,Hiroaki Nagano,Masayuki Ohta,Masafumi Inomata,Akira Chikamoto,Hideo Baba,Yusuke Watanabe,Kazuyoshi Nishihara,Masafumi Yasunaga,Koji Okuda,Shoji Natsugoe,Masafumi Nakamura

Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study

2019

Purpose Neoadjuvant therapy (NAT) is increasingly used to improve the prognosis of patients with borderline resectable pancreatic cancer (BRPC) albeit with little evidence of its advantage over upfront surgical resection. We analyzed the prognostic impact of NAT on patients with BRPC in a multicenter retrospective study.

Keywords:

Oncology
Neoadjuvant therapy
Surgery
Internal medicine
Retrospective cohort study
Chemoradiotherapy
Metastasis
Resectable Pancreatic Cancer
Medicine
Resection
Chemotherapy
Vascular surgery
Cancer
Pancreatic cancer
Abdominal surgery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations